profit from every ₹100 of sales.
₹0₹100
Zydus Lifesciences
₹1,189.90-1.33% today
+30.2% in 1 year
1-year low ₹860.601-year high ₹1,245.50
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay ₹23.55 for every ₹1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Zydus Lifesciences sold, what it kept, and what it did with the cash.
Sales went from ₹169 billion in 2023 to ₹267 billion in 2026, with ₹50.4 billion of profit last year.
SalesProfit
Zydus Lifesciences vs. similar companies
Zydus Lifesciences grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| Zydus Lifesciences | 23.6× · Fair price | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Zydus Lifesciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 168,778 | 190,215 | 225,738 | 267,197 | |
| 103,189 | 125,211 | 162,358 | 194,271 | |
| 28,528 | 45,392 | 59,793 | 57,866 | |
| 34,379 | 56,170 | 71,084 | 84,680 | |
| 19,603 | 38,595 | 45,255 | 50,400 | |
| 19.30 | 38.14 | 44.97 | 50.09 | |
| 61.1% | 65.8% | 71.9% | 72.7% | |
| 16.9% | 23.9% | 26.5% | 21.7% | |
| 11.6% | 20.3% | 20.0% | 18.9% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 257,564 | 292,808 | 372,017 | 524,066 |
| Cash | 4,878 | 4,130 | 8,268 | 8,552 |
| Total debt | 11,949 | 8,042 | 32,132 | 124,960 |
| Total liabilities | 60,681 | 71,792 | 108,433 | 228,244 |
| 175,158 | 198,295 | 239,531 | 271,114 | |
| 1,016 | 1,012 | 1,006 | 1,006 | |
| 10.9% | 17.6% | 17.1% | 13.4% | |
| 11.2% | 19.5% | 18.9% | 18.6% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 26,888 | 31,963 | 67,811 | 21,166 | |
| 10,309 | 9,066 | 16,937 | 26,715 | |
| 16,579 | 22,897 | 50,874 | -5,549 | |
| Dividends paid | 2,671 | 6,210 | 3,025 | 11,063 |
| 8,632 | 7,250 | 0 | – | |
| – | – | – | – |
Valuation
- 23.6×
- –
- 0.63
- 4.1×
- 4.4×
- –
- 15.4×
- -0.5%
- 4.2%
- 0.9%
Profitability
- 72.7%
- 21.7%
- 18.9%
- –
- 13.4%
- 14.7%
- –
- –
- –
- –
Growth
- +16.5%
- +37.4%
- –
- –
- −0.3%
Financial health
- 1.4×
- 0.46
- –
- 16.1×
- 1.27
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 18%of 946
Top 21%of 871
Top 39%of 563
Top 35%of 867
Bottom 37%of 986
0.9%of the share price, paid each year
On $1,000 invested$9a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
22.0% of its profit
Room to growStretchedMore than it earnsNews
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
56No pass
Benjamin Graham
47No pass
Philip Fisher
77Pass
Peter Lynch
91Pass
Joel Greenblatt
32No pass
Charlie Munger
55No pass
Terry Smith
44No pass
Questions about Zydus Lifesciences
Is Zydus Lifesciences a good stock to buy?
A solid business at a fair price. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Zydus Lifesciences AI analysis
What does Zydus Lifesciences do?
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It is in Drug Manufacturers - Specialty & Generic, based in Ahmedabad, India.
Does Zydus Lifesciences pay a dividend?
Yes. At today's price the dividend is 0.9% a year, about 22% of its yearly profit. In 2026 it paid out ₹11.1 billion in dividends.
Is Zydus Lifesciences stock halal?
Yes. Zydus Lifesciences passes our halal screen: its business is permitted and its debt is 11% of its market value, under the 30% limit. How we check
How has Zydus Lifesciences stock done over the past year?
Up 30.2% over the past twelve months, to ₹1,189.90. It traded between ₹860.60 and ₹1,245.50 and is 4.5% below its high.
Who are Zydus Lifesciences's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Zydus Lifesciences's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.